Biotechnology

Hochwertige TPUs in medizinischer Qualität dank Smart Factory: ICP DAS

by

HSINCHU, 18. Mai 2023 /PRNewswire/ – Intelligente Fertigung und strenge Prozesskontrolle verbessern die TPU-Qualität. ICP DAS – BMP (Biomedical Polymers), ein in Taiwan ansässiger Anbieter von TPU (thermoplastischem Polyurethan) in medizinischer Qualität, fungiert als Vorreiter, der IIoT-Systeme in einer Smart Factory einsetzt, um die Chargenkonsistenz bei der TPU-Produktion aufrechtzuerhalten. Das Unternehmen wird seine hochwertigen TPUs … Read more

TPU de grado médico de ICP DAS

by

-TPU de grado médico de alta calidad habilitado por la fábrica inteligente ICP DAS – BMP se exhibirá en Medtec China 2023 HSINCHU, 18 de mayo de 2023 /PRNewswire/ — La fabricación inteligente y el estricto control de procesos mejoran la calidad del TPU. ICP DAS – BMP (Biomedical Polymers), un proveedor de TPU (poliuretano … Read more

TPUs de classe médica e de alta qualidade, produzidos em uma fábrica inteligente: ICP DAS

by

HSINCHU, 18 de maio de 2023 /PRNewswire/ — A fabricação inteligente e um rigoroso controle de processos melhoram a qualidade do TPU. A ICP DAS – BMP (Polímeros Biomédicos), uma fornecedora de TPU (poliuretano termoplástico) de classe médica sediada em Taiwan, é uma empresa pioneira que implementa sistemas de IIoT em uma fábrica inteligente para … Read more

DISCOVERY LIFE SCIENCES REJOINT LE RÉSEAU MONDIAL DE PRESTATAIRES DE SERVICES D’AKOYA BIOSCIENCES POUR ACCÉLÉRER LA RECHERCHE EN IMMUNO-ONCOLOGIE

by

HUNTSVILLE, Alabama, 18 mai 2023 /PRNewswire/ — Discovery Life Sciences™ (Discovery), les Biospecimen and Biomarker Specialists™ (spécialistes des biospécimens et des biomarqueurs), a annoncé aujourd’hui sa qualification officielle comme l’un des fournisseurs de services mondiaux d’Akoya Biosciences. Le processus de qualification a évalué les compétences de Discovery en matière de coloration, d’imagerie et d’analyse, ce qui permet à … Read more

Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells

by

Data is being presented at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting MARLBOROUGH, Mass., May 18, 2023 /PRNewswire/ — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced pre-clinical data … Read more

Cystic Fibrosis Therapeutics Market to Grow Substantially by 2029

by

LONDON, May 18, 2023 /PRNewswire/ — Cystic fibrosis (CF), a challenging genetic disorder affecting the lungs and digestive system, has experienced remarkable advancements in therapeutics, instilling hope and enhancing the quality of life for those affected. This progressive disease involves the production of thick mucus, chronic lung infections, and compromised digestion. The realm of CF therapeutics … Read more

Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers

by

The publication in PLOS ONE shows that NAV-001 has robust single-dose efficacy against multiple mesothelin-expressing cancers and that tumor-produced Humoral Immunology-Oncology (HIO) factors negatively impact antibody drug internalization and efficacy. CHEYNEY, Pa., May 18, 2023 /PRNewswire/ — Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announces today a publication describing … Read more

BridGene Biosciences to Present at Hippo Pathway Targeted Drug Development Summit

by

SAN JOSE, Calif., May 18, 2023 /PRNewswire/ — BridGene Biosciences, Inc., a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, announced that Wolf Wiedemeyer, Ph.D., head of biology at BridGene, will be giving a presentation, titled “A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & … Read more

EXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TEST

by

Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS, May 18, 2023 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a previously published prospective, randomized study of more than 1,000 patients … Read more

BD Launches World’s First Spectral Cell Sorter with High-Speed Cell Imaging

by

BD FACSDiscover™ S8 Cell Sorter First to Combine Spectral Flow Cytometry with Real-Time Imaging Technology FRANKLIN LAKES, N.J., May 18, 2023 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the worldwide commercial launch of a new-to-world cell sorting instrument featuring two breakthrough technologies that enable researchers to … Read more